An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy
Yonsei University
Yonsei University
Canadian Cancer Trials Group
Centre Georges Francois Leclerc
University of Wisconsin, Madison
Ottawa Hospital Research Institute
Centre Leon Berard
Merck Sharp & Dohme LLC
Samsung Medical Center
SWOG Cancer Research Network
University of California, Irvine
Ottawa Hospital Research Institute
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
University of Kansas Medical Center
The Methodist Hospital Research Institute
University of Nebraska
Hoffmann-La Roche
Icahn School of Medicine at Mount Sinai
Dana-Farber Cancer Institute
EVIVE Biotechnology
Hoffmann-La Roche
Dana-Farber Cancer Institute
Wake Forest University Health Sciences
NSABP Foundation Inc
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Viatris Inc.
Columbia University
Lupin Ltd.
Asan Medical Center
Case Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
University of Wisconsin, Madison
Celgene
Academisch Ziekenhuis Maastricht
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
EVIVE Biotechnology
Mayo Clinic
Institute of Cancer Research, United Kingdom
Yonsei University
Amgen
Gema Biotech S.A.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Stanford University
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Sandoz
Sandoz
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center